Below are the most recent publications written about "Drug Dosage Calculations" by people in Profiles.
-
Hirshberg EL, Alexander JL, Asaro LA, Coughlin-Wells K, Steil GM, Spear D, Stone C, Nadkarni VM, Agus MSD. Performance of an Electronic Decision Support System as a Therapeutic Intervention During a Multicenter PICU Clinical Trial: Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT). Chest. 2021 09; 160(3):919-928.
-
Buchholz A, Ueberham L, Gorczynska K, Dinov B, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A. Initial apixaban dosing in patients with atrial fibrillation. Clin Cardiol. 2018 May; 41(5):671-676.
-
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018 02 16; 7(4).
-
Kraft WK. Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther. 2018 Jan; 103(1):112-119.
-
Fitzpatrick AM. Severe Asthma in Children: Lessons Learned and Future Directions. J Allergy Clin Immunol Pract. 2016 Jan-Feb; 4(1):11-9; quiz 20-1.
-
Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013 Nov 25; 2(6):e000535.
-
Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao LP. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011 Nov; 128(5):e1242-9.
-
Masters GA, Wang X, Hodgson L, Shea T, Vokes E, Green M. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer. 2011 Nov; 74(2):258-63.
-
Budnitz DS, Lewis LL, Shehab N, Birnkrant D. CDC and FDA response to risk of confusion in dosing Tamiflu oral suspension. N Engl J Med. 2009 Nov 05; 361(19):1913-4.